The E in ESG: Medtechs Are Getting To Grips With The ‘True Purpose’ Of Carbon Zero

Late starters health care and medtech are now making progress in the race to zero

BD and Boston Scientific exemplify the approach of “big medtech” as it knuckles down to meet global climate change responsibilities. But the industry will have to work together with health systems to achieve the larger race to zero goals – especially those of scope 3.  

Net Zero
• Source: Shutterstock

The medtech industry and health care sector in general have admittedly been slow starters in joining the race to carbon neutrality across their businesses. But much catch-up work is now ongoing, as evidenced from a recent UK-based industry conference on priorities and progress.

The UK earned bragging rights on the drive to sustainability in health care when its National Health Service (NHS) in...

More from ESG

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.